Adult Malignant Glioma Therapeutics Market to Hit US$ 4.68 Billion by 2031 | Exclusive Report by Growth Plus Reports

Newark, New Castle, USA, June 23, 2023 (GLOBE NEWSWIRE) — The market analysis of the global adult malignant glioma therapeutics market was conducted by Growth Plus Reports in 2022 and was valued at US$ 1.98 billion. The market is expected to hit a revenue CAGR of 9.57% to reach US$ 4.68 billion by 2031.

Analysis of the global market for adult malignant glioma therapeutics indicates that during the forecast period, revenue share is likely to increase significantly. Adult malignant gliomas are deadly brain tumors that develop from the brain’s supporting tissue. They are aggressive and deadly. They consist of anaplastic astrocytoma, anaplastic oligodendroglioma, and glioblastoma multiforme.

Key Takeaways: 

• Precision diagnoses and targeted treatments for adult malignant gliomas are due to advancements in genomic sequencing and molecular profiling. 
• For adult malignant gliomas, immunotherapy has emerged as a viable therapeutic option.
• The detection and management of adult malignant gliomas may be aided by AI and machine learning. 

Request a Free Sample PDF: https://www.growthplusreports.com/inquiry/request-sample/adult-malignant-glioma-therapeutics-market/8911

                             Adult Malignant Glioma Therapeutics Market Scope

Competitive Landscape

A list of the companies operating in the global market for adult malignant glioma therapeutics includes: 

• Bristol-Myers Squibb Company
• Hoffmann-La Roche Ltd
• Pfizer Inc
• Sun Pharmaceuticals Ltd
• Merck & Co., Inc
• Bio-Rad Laboratories

Market Drivers and Restraints: 

The global adult malignant glioma therapeutics market revenue is driven by the increasing number of cancer cases and increasing demand for precision medicine tailored related to patient issues. Furthermore, the rising investments and the government’s initiative in the research and development of cancer cure and therapeutics is contributing to the market revenue growth.  

However, due to the availability of limited treatment options and the potential side effects of these drugs, the adult malignant glioma therapeutics market revenue growth is expected to be restrained. 

Market Segmentation: 

Segmentation By Type

Based on the type, the adult malignant glioma therapeutics market is dominated by the glioblastoma multiforme segment, with the highest revenue share. As the most prevalent and aggressive kind of adult malignant glioma, it accounts for a significant portion of income. Moreover, glioblastoma multiforme has a dismal prognosis and a median survival period of just 15 months, and the illness is linked to high morbidity and fatality rates resulting in revenue growth. 

Segmentation By Therapy

Based on the therapy, the chemotherapy segment dominates the global adult malignant glioma therapeutics market with the largest revenue share. This large revenue share is attributed to it being the most common treatment option for treating most types of cancer. Additionally, chemotherapy successfully inhibits the development of the tumor, lessens the symptoms, and extends survival in some individuals, contributing to the segment’s revenue growth. 

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global adult malignant glioma therapeutics market. Adult malignant gliomas are quite common and are frequent in North America. Due to the rising prevalence of diseases, there is a great need for efficient therapies, which propels the market’s expansion. With its highly established healthcare infrastructure, processes, and facilities, North America greatly focuses on research and development.

Request for Customization – https://www.growthplusreports.com/inquiry/customization/adult-malignant-glioma-therapeutics-market/8911

Report Coverage 

Growth Plus Reports carried out extensive market research on the adult malignant glioma therapeutics market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3.  Opportunities
5. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY TYPE
   1. Glioblastoma Multiforme
   2. Anaplastic Astrocytoma
   3. Anaplastic Oligoastrocytoma
   4. Other
6. GLOBAL ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET – ANALYSIS & FORECAST, BY THERAPY
   1. Chemotherapy
   2. Targeted Therapy
   3. Immunotherapy

ADULT MALIGNANT GLIOMA THERAPEUTICS MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8911

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Orthopedic Biomaterials Market by Material Type (Polymers, Ceramics & Bioactive Glasses, Calcium Phosphate Cement), Application (Joint Replacement/Reconstruction, Orthobiologics, Viscosupplementation)-Global Outlook & Forecast 2023-2031

Specialty Generics Market by Route of Administration (Injectables, Oral drugs, Others), Indication (Oncology, Inflammatory Conditions, Multiple Sclerosis) End-Use: Specialty Pharmacy, Retail Pharmacy, Hospital Pharmacy) – Global Outlook & Forecast 2023-2031

Gastric Motility Disorder Drugs Market by Drug Class (Cholinergic Agonists, Prokinetic Agents), Route of Administration (Oral, Subcutaneous, Intramuscular), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Nephrology Drugs Market by Drug Class (ACE Inhibitors, Beta Blockers), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies)– Global Outlook & Forecast 2023-2031

Diabetes Drugs Market by Drugs (Oral Anti-Diabetic Drugs, Insulin), Type (Type 1, Type 2), Distribution Channel (Hospital Pharmacies, Retail Pharmacies)– Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.